121 results
Page 5 of 7
8-K
EX-99.1
fhrzyts
14 May 19
MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update
9:11pm
DEFA14A
s1hw1wseakp5dw hsov
29 Apr 19
Additional proxy soliciting materials
4:24pm
DEF 14A
bo8a4d jcqg2g
29 Apr 19
Definitive proxy
4:20pm
PRE 14A
ppixx
12 Apr 19
Preliminary proxy
4:10pm
10-K
EX-10.25
k219hg4p5a10 03hw
26 Mar 19
Annual report
5:13pm
10-K
EX-10.19
wspcjcrhm
26 Mar 19
Annual report
5:13pm
10-K
EX-10.21
twn 8iafe
26 Mar 19
Annual report
5:13pm
10-K
EX-10.22
p8t3cn
26 Mar 19
Annual report
5:13pm
10-K
utiuyvu f0on
26 Mar 19
Annual report
5:13pm
10-K
EX-10.23
8xwzb1jaa
26 Mar 19
Annual report
5:13pm
10-K
EX-2.1
pugmlsx1fam
26 Mar 19
Annual report
5:13pm
10-K
EX-10.20
wtuvc5osp01xqelakb9m
26 Mar 19
Annual report
5:13pm
8-K
EX-99.1
h9th57 hqlt
26 Mar 19
MeiraGTx Reports Full Year 2018 Financial Results
4:14pm
8-K
EX-10.1
ypzz q7bo4
4 Mar 19
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-99.1
1r2ozumnk5lpmnsk
27 Feb 19
MeiraGTx Announces $80 Million Private Placement of Ordinary Shares
8:26am
8-K
EX-99.1
ivsrdp1ngl 5y
5 Feb 19
MeiraGTx Enters into Strategic Collaboration with Janssen to Develop and Commercialize Gene Therapy Treatments for Inherited Retinal Diseases
5:10pm
8-K
EX-10.1
kft4r9k9c1au4klue48d
20 Dec 18
Entry into a Material Definitive Agreement
4:35pm
8-K
EX-99.1
fjdlfv3k
8 Nov 18
MeiraGTx Reports Third Quarter 2018 Financial Results and Provides Corporate Update
8:35am